- Home
- CVAC vs PCRX Comparison
CVAC vs PCRX Comparison
Compare CVAC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- PCRX
- Stock Information
- Founded
- CVAC 2000
- PCRX 2006
- Country
- CVAC Germany
- PCRX United States
- Employees
- CVAC N/A
- PCRX N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CVAC Health Care
- PCRX Health Care
- Exchange
- CVAC Nasdaq
- PCRX Nasdaq
- Market Cap
- CVAC 1.2B
- PCRX 1.2B
- IPO Year
- CVAC 2020
- PCRX 2011
- Fundamental
- Price
- CVAC $5.41
- PCRX $21.85
- Analyst Decision
- CVAC Hold
- PCRX Buy
- Analyst Count
- CVAC 3
- PCRX 8
- Target Price
- CVAC $6.83
- PCRX $28.38
- AVG Volume (30 Days)
- CVAC 974.1K
- PCRX 506.9K
- Earning Date
- CVAC 08-14-2025
- PCRX 07-29-2025
- Dividend Yield
- CVAC N/A
- PCRX N/A
- EPS Growth
- CVAC N/A
- PCRX N/A
- EPS
- CVAC 0.87
- PCRX N/A
- Revenue
- CVAC $566,039,775.00
- PCRX $702,772,000.00
- Revenue This Year
- CVAC N/A
- PCRX $7.92
- Revenue Next Year
- CVAC $24.04
- PCRX $11.02
- P/E Ratio
- CVAC $6.24
- PCRX N/A
- Revenue Growth
- CVAC 787.60
- PCRX 3.08
- 52 Week Low
- CVAC $2.37
- PCRX $11.16
- 52 Week High
- CVAC $5.72
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- CVAC 59.79
- PCRX 33.91
- Support Level
- CVAC $5.42
- PCRX $22.24
- Resistance Level
- CVAC $5.49
- PCRX $23.58
- Average True Range (ATR)
- CVAC 0.07
- PCRX 0.77
- MACD
- CVAC -0.06
- PCRX -0.05
- Stochastic Oscillator
- CVAC 36.67
- PCRX 5.16
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.